Cost-effectiveness of bortezomib for multiple myeloma: a systematic review

References

• RaabMSPodarKBreitkreutzIRichardsonPGAndersonKCMultiple myelomaLancet2009374968632433919541364
   PubMed Web of Science ®Google Scholar
• ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics, 2002CA Cancer J Clin2005557410815761078
   PubMed Web of Science ®Google Scholar
• PulteDRedanielMTBrennerHJansenLJeffreysMRecent improvement in survival of patients with multiple myeloma: variation by ethnicityLeuk Lymphoma20145551083108923879201
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA Phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med2003348262609261712826635
   PubMed Web of Science ®Google Scholar
• JagannathSBarlogieBBerensonJA Phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBr J Haematol200412716517215461622
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med20053522487249815958804
   PubMed Web of Science ®Google Scholar
• San MiguelJFSchlagRKhuagevaNKPersistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJ Clin Oncol20123144845523233713
   PubMed Web of Science ®Google Scholar
• HarousseauJLAttalMAvet-LoiseauHBortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trialJ Clin Oncol201028304621462920823406
   PubMed Web of Science ®Google Scholar
• RothwellPMExternal validity of randomised controlled trials: “to whom do the results of this trial apply?Lancet20053659453829315639683
   PubMed Web of Science ®Google Scholar
• BellCMUrbachDRRayJGBias in published cost effectiveness studies: systematic reviewBMJ2006332754369970316495332
   PubMed Web of Science ®Google Scholar
• Cost effectiveness and strategic planning (WHO-CHOICE) Available from: http://www.who.int/choice/costs/CER_thresholds/en/Accessed March 6, 2016
   Google Scholar
• KouroukisTWhiteDKruseMLawrenceDTrambitasCCheungMCCost-utility of bortezomib in induction treatment prior to autologous stem-cell transplantation (ASCT) in previously untreated multiple myeloma patients in CanadaBlood2013122211735
   Web of Science ®Google Scholar
• MuchaJWalczakJTronczynskiKSkrzekowska-BaranIBortezomib-based regimens used as induction in newly diagnosed multiple myeloma (ndMM) patients eligible for stem cell transplantation (SCT) the cost-utility analysisValue Health2014173A229
   Web of Science ®Google Scholar
• Van Beurden-TanCRosinolLDielsJCost-effectiveness of induction treatment with bortezomib added to thalidomide and dexamethasone in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation in GermanyValue Health2013167A409A410
   Web of Science ®Google Scholar
• RickertJBHornbergerJLiwingJAschanJGjonnesLDhawanRBortezomib is cost-effective for first-line treatment of multiple myeloma in SwedenValue Health2010133A40
   Web of Science ®Google Scholar
• GarrisonLPJrWangSTHuangHThe cost-effectiveness of initial treatment of multiple myeloma in the US with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatmentOncologist2013181273623299777
   PubMed Web of Science ®Google Scholar
• OsterGBergerABornheimerRBinderGNagarwalaYCost-effectiveness of lenalidomide and bortezomib in patients with previously untreated multiple myeloma (MM)Blood2013122215604
   Web of Science ®Google Scholar
• PicotJCooperKBryantJCleggAJThe clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluationHealth Technol Assess201115411204
   Web of Science ®Google Scholar
• YoongKAttardCJivrajFShustikCReeceDCost effectiveness analysis of bortezomib in previously untreated multiple myeloma patients in CanadaValue Health2009127A272
   Web of Science ®Google Scholar
• CavenaghJDBelchARHulinCCost-effectiveness in newly diagnosed multiple myeloma (NDMM): lenalidomide plus low-dose dexamethasone (RD) versus bortezomib plus melphalan and prednisone (VMP)Haematologica201499379
   Web of Science ®Google Scholar
• BagustAHaycoxAMujica-MotaRDhawanRDuboisDCost-effectiveness of bortezomib (VELCADE) for relapsed and refractory multiple myelomaValue Health200476670
   Web of Science ®Google Scholar
• MehtaJDuffSBGuptaSCost effectiveness of bortezomib in the treatment of advanced multiple myelomaManag Care Interface2004179526115521286
   PubMedGoogle Scholar
• FelixJAlmeidaJVandewalleBA comprehensive cost-effectiveness analysis of lenalidomide for multiple myeloma patients who have received at least one prior therapyValue Health2012154A218
   Web of Science ®Google Scholar
• FragoulakisVKastritisEPsaltopoulouTManiadakisNEconomic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in GreeceCancer Manag Res201351374823596356
   PubMedGoogle Scholar
• HornbergerJRickertJDhawanRLiwingJAschanJLothgrenMThe cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspectiveEur J Haematol201085648449120846301
   PubMed Web of Science ®Google Scholar
• JiangYSpencerMGauthierAPacouMA cost-effectiveness analysis for second-line treatment of relapsed/refractory (RR) multiple myeloma (MM) in the United KingdomValue Health2011147A452
   Google Scholar
• LiwingJGjonnesLSandbergIThe cost-effectiveness of bortezomib for relapsed/refractory multiple myeloma – a nordic comparisonValue Health2009127A273
   Web of Science ®Google Scholar
• MollerJNicklassonLMurthyACost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomibJ Med Econ201114669069721892856
   PubMedGoogle Scholar
• HarousseauJLAttalMAvet-LoiseauHBortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 Phase III trialJ Clin Oncol201028304621462920823406
   PubMed Web of Science ®Google Scholar
• MorganGJDaviesFEGregoryWMCyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsHaematologica201297344245022058209
   PubMed Web of Science ®Google Scholar
• RosiñolLOriolATeruelAISuperiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized Phase 3 PETHEMA/GEM studyBlood201212081589159622791289
   PubMed Web of Science ®Google Scholar
• San MiguelJFSchlagRKhuagevaNKBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med2008359990691718753647
   PubMed Web of Science ®Google Scholar
• HulinCFaconTRodonPEfficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trialJ Clin Oncol2009274848485719752334
   PubMed Web of Science ®Google Scholar
• FaconTMaryJYHulinCMelphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trialLancet20073701209121817920916
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSCaravitaTOral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialLancet200636782583116530576
   PubMed Web of Science ®Google Scholar
• MorganGJDaviesFEGregoryWMCyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationBlood201111851231123821652683
   PubMed Web of Science ®Google Scholar
• MM-015 InvestigatorsContinuous lenalidomide treatment for newly diagnosed multiple myelomaN Engl J Med2012366191759176922571200
   PubMed Web of Science ®Google Scholar
• BenboubkerLDimopoulosMADispenzieriALenalidomide and dexamethasone in transplant-ineligible patients with myelomaN Engl J Med20143711090691725184863
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• Multiple Myeloma (009) Study InvestigatorsLenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaN Engl J Med2007357212133214218032763
   PubMed Web of Science ®Google Scholar
• Multiple Myeloma (010) Study InvestigatorsLenalidomide plus dexamethasone for relapsed or refractory multiple myelomaN Engl J Med2007357212123213218032762
   PubMed Web of Science ®Google Scholar
• van AgthovenMSegerenCMBuijtIA cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised Phase III studyEur J Cancer20044081159116915110879
   PubMed Web of Science ®Google Scholar
• KontodimopoulosNLAletrasVHPaliourasDMapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instrumentsValue Health20091281151115719558372
   PubMed Web of Science ®Google Scholar
• PoochUWWallJADiscrete Event Simulation: A Practical Approach4Boca Raton, FLCRC Press1992
   Google Scholar
• StuartEABradshawCPLeafPJAssessing the generalizability of randomized trial results to target populationsPrev Sci201516347548525307417
   PubMed Web of Science ®Google Scholar
• PalumboAHajekRDelforgeMContinuous lenalidomide treatment for newly diagnosed multiple myelomaN Engl J Med2012366191759176922571200
   PubMed Web of Science ®Google Scholar